Sanofi is the latest major pharmaceutical company to increase its investments in the U.S., partly in response to President Donald Trump’s tariff threats. Reuters reports that the company plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research.

The pharmaceutical company plans to enhance its manufacturing capabilities in the U.S. by investing directly in its Sanofi facilities and collaborating with other local manufacturers. Sanofi stated that a significant portion of the funds will also be allocated to boost research and development efforts in the country.

Sanofi’s CEO, Paul Hudson, remarked: “Our expected investments in the U.S. will be substantial and will help ensure the production of key medicines in the U.S.”

Several other pharmaceutical companies, including Roche, Eli Lilly, Johnson & Johnson, and Novartis, have made similar announcements in recent weeks.